Angela Lowenstern1, Jingjing Wu2, Steven M Bradley3, Alexander C Fanaroff4, James E Tcheng4, Tracy Y Wang4. 1. Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC. Electronic address: angela.sandelin@dm.duke.edu. 2. Duke Clinical Research Institute, Durham, NC. 3. Minneapolis Heart Institute, Minneapolis, MN. 4. Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC.
Abstract
BACKGROUND: Hybrid revascularization, combining percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), may be used differently across hospitals. How outcomes compare with multivessel PCI is unknown. METHODS: We studied hybrid revascularization use in patients in the National Cardiovascular Data Registry from 2009 to 2017 who underwent PCI for multivessel coronary artery disease (CAD) at 711 hospitals, excluding patients with prior CABG, acute ST-elevation myocardial infarction, emergency/salvage CABG, or PCI without stent placement. In-hospital mortality associated with hybrid revascularization versus multivessel PCI was compared using a multivariable logistic model. RESULTS: Among 775,000 patients with multivessel CAD, 1,126 (0.2%) underwent hybrid revascularization and 256,865 (33%) were treated with multivessel PCI. Although 358 (50.4%) hospitals performed hybrid revascularizations, most (97.3%) performed <1 per year. Most patients (68.7%) treated with hybrid revascularization underwent CABG after PCI; only 79.4% of these patients were discharged on P2Y12 inhibitors. Patients who underwent hybrid revascularization were younger and more likely to have significant left main or proximal left anterior descending disease. Unadjusted in-hospital mortality rates were higher among patients treated with hybrid revascularization than multivessel PCI (1.5% vs 0.9%, P = .02), a difference that was not significant after multivariable adjustment (odds ratio = 1.54, 95% CI = 0.92-2.59). CONCLUSIONS: Hybrid revascularization remains an infrequently used treatment modality for multivessel CAD. Risk-adjusted in-hospital mortality was no different between hybrid revascularization and multivessel PCI; however, patients who underwent hybrid revascularization were less likely to be discharged on P2Y12 inhibitor therapy despite stent implantation.
BACKGROUND: Hybrid revascularization, combining percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), may be used differently across hospitals. How outcomes compare with multivessel PCI is unknown. METHODS: We studied hybrid revascularization use in patients in the National Cardiovascular Data Registry from 2009 to 2017 who underwent PCI for multivessel coronary artery disease (CAD) at 711 hospitals, excluding patients with prior CABG, acute ST-elevation myocardial infarction, emergency/salvage CABG, or PCI without stent placement. In-hospital mortality associated with hybrid revascularization versus multivessel PCI was compared using a multivariable logistic model. RESULTS: Among 775,000 patients with multivessel CAD, 1,126 (0.2%) underwent hybrid revascularization and 256,865 (33%) were treated with multivessel PCI. Although 358 (50.4%) hospitals performed hybrid revascularizations, most (97.3%) performed <1 per year. Most patients (68.7%) treated with hybrid revascularization underwent CABG after PCI; only 79.4% of these patients were discharged on P2Y12 inhibitors. Patients who underwent hybrid revascularization were younger and more likely to have significant left main or proximal left anterior descending disease. Unadjusted in-hospital mortality rates were higher among patients treated with hybrid revascularization than multivessel PCI (1.5% vs 0.9%, P = .02), a difference that was not significant after multivariable adjustment (odds ratio = 1.54, 95% CI = 0.92-2.59). CONCLUSIONS: Hybrid revascularization remains an infrequently used treatment modality for multivessel CAD. Risk-adjusted in-hospital mortality was no different between hybrid revascularization and multivessel PCI; however, patients who underwent hybrid revascularization were less likely to be discharged on P2Y12 inhibitor therapy despite stent implantation.
Authors: Michael E Halkos; Thomas A Vassiliades; John S Douglas; Douglas C Morris; S Tanveer Rab; Henry A Liberman; Habib Samady; Patrick D Kilgo; Robert A Guyton; John D Puskas Journal: Ann Thorac Surg Date: 2011-09-21 Impact factor: 4.330
Authors: Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting Journal: J Am Coll Cardiol Date: 2011-11-07 Impact factor: 24.094
Authors: L David Hillis; Peter K Smith; Jeffrey L Anderson; John A Bittl; Charles R Bridges; John G Byrne; Joaquin E Cigarroa; Verdi J Disesa; Loren F Hiratzka; Adolph M Hutter; Michael E Jessen; Ellen C Keeley; Stephen J Lahey; Richard A Lange; Martin J London; Michael J Mack; Manesh R Patel; John D Puskas; Joseph F Sabik; Ola Selnes; David M Shahian; Jeffrey C Trost; Michael D Winniford Journal: J Am Coll Cardiol Date: 2011-11-07 Impact factor: 24.094
Authors: Ralf E Harskamp; Johannes O Bonatti; David X Zhao; John D Puskas; Robbert J de Winter; John H Alexander; Michael E Halkos Journal: J Thorac Cardiovasc Surg Date: 2013-11-23 Impact factor: 5.209
Authors: Mariusz Gąsior; Michael Oscar Zembala; Mateusz Tajstra; Krzysztof Filipiak; Marek Gierlotka; Tomasz Hrapkowicz; Michał Hawranek; Lech Poloński; Marian Zembala Journal: JACC Cardiovasc Interv Date: 2014-11-17 Impact factor: 11.195
Authors: Ezra A Amsterdam; Nanette K Wenger; Ralph G Brindis; Donald E Casey; Theodore G Ganiats; David R Holmes; Allan S Jaffe; Hani Jneid; Rosemary F Kelly; Michael C Kontos; Glenn N Levine; Philip R Liebson; Debabrata Mukherjee; Eric D Peterson; Marc S Sabatine; Richard W Smalling; Susan J Zieman Journal: J Am Coll Cardiol Date: 2014-09-23 Impact factor: 24.094
Authors: Thomas A Vassiliades; Patrick D Kilgo; John S Douglas; Vasilis C Babaliaros; Peter C Block; Habib Samady; Christopher U Cates; S Tanveer Rab; Douglas C Morris Journal: Innovations (Phila) Date: 2009-11
Authors: Marzia Leacche; John G Byrne; Natalia S Solenkova; Brendan Reagan; Tahir I Mohamed; Joseph L Fredi; David X Zhao Journal: J Thorac Cardiovasc Surg Date: 2012-04-25 Impact factor: 5.209
Authors: Ralf E Harskamp; J Matthew Brennan; Ying Xian; Michael E Halkos; John D Puskas; Vinod H Thourani; James S Gammie; Bradley S Taylor; Robbert J de Winter; Sunghee Kim; Sean O'Brien; Eric D Peterson; Jeffrey G Gaca Journal: Circulation Date: 2014-07-23 Impact factor: 29.690
Authors: Patrick W Serruys; Marie-Claude Morice; A Pieter Kappetein; Antonio Colombo; David R Holmes; Michael J Mack; Elisabeth Ståhle; Ted E Feldman; Marcel van den Brand; Eric J Bass; Nic Van Dyck; Katrin Leadley; Keith D Dawkins; Friedrich W Mohr Journal: N Engl J Med Date: 2009-02-18 Impact factor: 91.245
Authors: Edward L Hannan; Yi-Feng Wu; Kimberly Cozzens; Jacqueline Tamis-Holland; Frederick S K Ling; Alice K Jacobs; Ferdinand J Venditti; Peter B Berger; Gary Walford; Spencer B King Iii Journal: J Geriatr Cardiol Date: 2021-03-28 Impact factor: 3.327